Loading...
XASXMYX
Market cap240mUSD
Dec 27, Last price  
4.75AUD
1D
0.00%
1Q
3.26%
Jan 2017
-82.34%
IPO
-37.50%
Name

Mayne Pharma Group Ltd

Chart & Performance

D1W1MN
XASX:MYX chart
P/E
—
P/S
0.99
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-0.40%
Rev. gr., 5y
-5.87%
Revenues
388m
+111.43%
140,112820,8141,039,88137,043,98848,768,00051,078,00082,262,000142,181,000140,324,000267,279,999572,595,000530,313,000525,207,999456,985,000400,781,000157,147,000183,586,000388,151,000
Net income
-174m
L-44.94%
-1,823,975-3,472,806-3,761,3183,253,1191,679,0006,153,000-2,843,00021,290,0007,759,00037,355,00088,567,000-133,984,000-279,203,000-92,789,000-208,423,000-281,286,000-316,419,000-174,233,000
CFO
-15m
L-64.52%
-1,238,716-3,025,908-3,589,83210,255,6004,086,00013,387,0006,845,00026,136,00022,420,00053,504,000-15,237,000121,498,000106,606,00099,777,00047,256,000-16,617,999-43,123,000-15,300,000
Dividend
Jan 18, 202310.88 AUD/sh
Earnings
Feb 24, 2025

Profile

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
URL
http://www.maynepharma.com/
IPO date
Jun 29, 2007
Employees
850
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
388,151
111.43%
183,586
16.82%
157,147
-60.79%
Cost of revenue
432,936
356,475
303,154
Unusual Expense (Income)
NOPBT
(44,785)
(172,889)
(146,007)
NOPBT Margin
Operating Taxes
(21,468)
47,745
74,501
Tax Rate
NOPAT
(23,317)
(220,634)
(220,508)
Net income
(174,233)
-44.94%
(316,419)
12.49%
(281,286)
34.96%
Dividends
(45,292)
Dividend yield
12.67%
Proceeds from repurchase of equity
(10,932)
(6,223)
BB yield
2.92%
1.74%
Debt
Debt current
3,820
14,427
407,993
Long-term debt
42,181
37,676
11,346
Deferred revenue
4,598
(1)
Other long-term liabilities
332,698
269,737
108,681
Net debt
(118,614)
(177,137)
344,386
Cash flow
Cash from operating activities
(15,300)
(43,123)
(16,618)
CAPEX
(7,950)
(219,585)
(11,853)
Cash from investing activities
53,449
473,485
(28,526)
Cash from financing activities
(19,850)
(431,475)
37,013
FCF
2,946
117,655
(268,298)
Balance
Cash
149,278
229,240
97,080
Long term investments
15,337
(22,127)
Excess cash
145,207
220,061
67,096
Stockholders' equity
454,188
634,360
538,230
Invested Capital
680,500
715,311
992,257
ROIC
ROCE
EV
Common stock shares outstanding
79,620
81,246
81,246
Price
4.71
7.05%
4.40
-12.00%
5.00
-21.88%
Market cap
375,010
4.90%
357,482
-12.00%
406,229
-21.88%
EV
256,396
180,345
742,962
EBITDA
26,836
(107,448)
(90,826)
EV/EBITDA
9.55
Interest
34,501
10,454
11,525
Interest/NOPBT